Cellectar reports Q1 net loss of $8.6M; cash at $12.7M with runway into Q4 2023

Cellectar Biosciences, Inc.

2023-Q1 EPS reported -$0.76

Net loss of ($8.6M) or ($0.76)/share vs ($6.1M) or ($1.00)/share in Q1 2022.
Cash and equivalents $12.7M at March 31, 2023, down from $19.9M at Dec 31, 2022.
R&D expense rose to $6.7M from $3.9M YoY on clinical, manufacturing costs.
G&A expense decreased to $2.1M from $2.3M YoY driven by lower professional fees.
Enrolling pivotal iopofosine trial in Waldenstrom's; topline data expected in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cellectar Biosciences, Inc. reported three months ended March 31, 2023 results: net income ($8.6) million, EPS ($0.76) per share.

Period: three months ended March 31, 2023
Net income: ($8.6) million
EPS: ($0.76) per share
Result: reported results

Exact text from the filing

The net loss attributable to common stockholders for the three months ended March 31, 2023 was ($8.6) million, or ($0.76) per share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cellectar Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-055815

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.